^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NUP93 (Nucleoporin 93)

    i
    Other names: NUP93, Nucleoporin 93, Nuclear Pore Complex Protein Nup93, 93 KDa Nucleoporin, Nucleoporin 93kDa, Nucleoporin Nup93, KIAA0095, NIC96
    12d
    Deciphering the eRNA landscape and revealing target aberrant pathways in prostate cancer. (PubMed, BMC Cancer)
    These findings indicate that eRNAs may contribute to prostate cancer biology and could serve as useful markers for prognosis and pathway characterization.
    Journal
    |
    BICD1 (BICD Cargo Adaptor 1) • NUP93 (Nucleoporin 93)
    1m
    Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma. (PubMed, Theranostics)
    High ARMC12, MYC, NUP62, NUP93, or NUP98 levels served as markers of unfavorable patient outcomes in clinical cohorts. These findings collectively demonstrate that dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven NPC biogenesis during NB progression.
    Journal
    |
    NUP98 (Nucleoporin 98 And 96 Precursor 2) • NUP62 (Nucleoporin 62) • NUP93 (Nucleoporin 93)
    3ms
    Biomarkers Driving Precision Medicine in Non-functioning Pituitary Neuroendocrine Tumors: A Systematic Review of Recent Literature. (PubMed, J Clin Endocrinol Metab)
    Overall, the lineage-aligned synthesis indicates that NF-PitNETs progress through diverse molecular pathways, with each subtype dominated by distinct regulatory networks. Although many biomarkers show promise, most remain exploratory, highlighting the need for harmonised methods and multicentre validation to support precision diagnostics and prognostic modelling.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • LGALS1 (Galectin 1) • VIM (Vimentin) • MMP1 (Matrix metallopeptidase 1) • NUP93 (Nucleoporin 93) • MCM7 (Minichromosome Maintenance Complex Component 7) • MIR486-1 (MicroRNA 486-1)
    9ms
    LIMK1 as a Novel Kinase of β-Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5. (PubMed, Adv Sci (Weinh))
    Furthermore, the combination of LIMK1 and CDK5 inhibitors significantly suppresses metastasis in multiple models. This work highlights LIMK1 as a novel regulatory and targetable kinase of β-catenin, informing the treatment of advanced cancer.
    Journal
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1) • NUP93 (Nucleoporin 93) • CDK5 (Cyclin Dependent Kinase 5) • LIMK1 (LIM Domain Kinase 1)
    over1year
    Transcription Factor yin-Yang 1 augments nucleoporin 93 oncogene activity and modulates bladder Cancer malignancy. (PubMed, Toxicol In Vitro)
    Our results uncovered transcription factor YY1 as a positive regulator of NUP93 expression, and NUP93 serves as an oncogenic factor to sustain the malignancy of bladder cancer cells. These findings suggest that targeting the YY1-NUP93 axis could offer novel therapeutic strategies for bladder cancer treatment.
    Journal
    |
    NUP93 (Nucleoporin 93) • YY1 (YY1 Transcription Factor)
    almost2years
    Nucleoporin 93 Regulates Cancer Cell Growth and Stemness in Bladder Cancer via Wnt/β-Catenin Signaling. (PubMed, Mol Biotechnol)
    Nup93 knockdown also suppressed the tumor formation of BLCA cells in vivo. Nup93 regulates BLCA cell growth and stemness via the Wnt/β-catenin pathway, suggesting its potential as a prognostic marker and therapeutic target in BLCA.
    Journal
    |
    ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • NUP93 (Nucleoporin 93)
    over2years
    Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression. (PubMed, Hum Cell)
    To conclude, this study has shown that NUP93 has pro-tumor properties in ESCC and that HECTD1 functions as an upstream regulator of NUP93 in ESCC. These findings may contribute to the investigation of potential therapeutic targets in ESCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • NUP93 (Nucleoporin 93) • UBE2H (Ubiquitin Conjugating Enzyme E2 H) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    PD-L1 expression
    over2years
    A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk (ASH 2023)
    Our findings indicate that creating a biosignature using transcriptomic features in addition to previously used prognostic factors may improve prediction of outcome in MM. The model has to be tested in larger clinical material.
    Clinical
    |
    NUP93 (Nucleoporin 93) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • CASP4 (Caspase 4) • VMP1 (Vacuole Membrane Protein 1) • SOX13 (SRY-Box Transcription Factor 13)
    3years
    Expanding Molecular Spectrum of Quadruple Wild-type GIST and GIST-like Tumors: NGS study of a Series of 17 Cases (USCAP 2023)
    Our study revealed 6 new cases of quadruple wild-type GIST or GIST-like tumors with possible oncogenic driver alterations (2.4 % of all our archival cases of GIST). While the case with BCOR-CCNB3 fusion rather represents a CD117-positive GIST-like BCOR -rearranged sarcoma, the remaining 5 cases probably belong to the category of true quadruple wild-type GIST. Whereas mutations in MAX and TP53 were already described previously, we are not aware of any study reporting on mutations of ATM , GNAQ and NUP93 in GIST.
    Clinical • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • FGFR1 (Fibroblast growth factor receptor 1) • ARID1A (AT-rich interaction domain 1A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • GNAQ (G Protein Subunit Alpha Q) • ETV6 (ETS Variant Transcription Factor 6) • BCOR (BCL6 Corepressor) • FGF4 (Fibroblast growth factor 4) • ANO1 (Anoctamin 1) • CHD4 (Chromodomain Helicase DNA Binding Protein 4) • NUP93 (Nucleoporin 93) • MAX (MYC Associated Factor X)
    |
    TP53 mutation • KRAS mutation • EGFR mutation • BRAF mutation • ATM mutation • KIT mutation • NF1 mutation • RAS mutation • FGFR1 mutation • CBL mutation • PDGFRA mutation • NUP93 mutation • PDGFR wild-type
    |
    TruSight Oncology 500 Assay • Archer® FusionPlex® Sarcoma kit
    over3years
    Nuclear Membrane Protein SUN5 Is Highly Expressed and Promotes Proliferation and Migration in Colorectal Cancer by Regulating the ERK Pathway. (PubMed, Cancers (Basel))
    PD0325901 decreased the level of pERK1/2 to inhibit cell proliferation and migration, which was partially reversed by SUN5 overexpression, indicating that drug resistance existed in patients with high SUN5 expression...Furthermore, we found that SUN5 regulated the ERK pathway via Nesprin2 mediation and promoted the nuclear translocation of pERK1/2 by interacting with Nup93. Thus, these findings indicated that highly expressed SUN5 promoted CRC proliferation and migration by regulating the ERK pathway, which may contribute to the clinical diagnosis and new treatment strategies for CRC.
    Journal
    |
    NUP93 (Nucleoporin 93)
    |
    Gomekli (mirdametinib)
    over3years
    Genome-wide DNA Methylation Differences in Non-functioning Pituitary Adenomas With and Without Postsurgical Progression. (PubMed, J Clin Endocrinol Metab)
    In this exploratory study, DNA methylation patterns in NFPA patients were associated with postoperative tumor progression requiring reintervention. The DMPs included genes that have been previously associated with tumor development. Our study is a step toward finding epigenetic signatures to predict tumor progression in patients with NFPA.
    Journal • Epigenetic controller
    |
    LGALS1 (Galectin 1) • NUP93 (Nucleoporin 93)
    almost4years
    Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. (PubMed, Cell Rep)
    Congruently, myristoylated peptides corresponding to the nuclear translocation signals of SMAD and ERK can inhibit tumor growth and metastasis. Our study sheds light on an emerging hallmark of advanced tumors, which derive benefit from robust nucleocytoplasmic transport.
    Journal
    |
    EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • NUP93 (Nucleoporin 93)
    |
    MYC overexpression